Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
about
Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant AbsorptionEfficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load.Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies.AASLD guidelines for treatment of chronic hepatitis B.Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis.Weight change after antiretroviral therapy and mortality.Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected ChildrenTenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical TenofovirUse of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.Pharmacokinetic considerations in the use of antivirals in neonates.Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.Antiviral treatment of HBV positive pregnant women: an additional tool to reduce perinatal transmission.Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis
P2860
Q28554369-28A0D6C4-D1FB-4D1E-A425-495EA8FC9ABEQ33829957-C913BAC4-F279-4420-891A-05ECAEB4CF4BQ34429204-939CF02E-EF3B-4BC0-A4FA-3F0EE6E9AC8BQ34470986-0E879780-8043-4595-84B0-A6CCA4D7BFA7Q34501660-F7311435-D09B-4EA2-AAD7-97845597194FQ35751105-EA99E9C4-C907-47E6-8CE7-FDFB6B4FBD58Q35974655-6BCA2AC5-2720-476A-8CEC-956B7C67385DQ36070335-C241433D-FF08-4B94-92DE-38B76EF8D7DEQ36146022-A332E2F7-5A75-41A1-81C6-E28F64C3265FQ36706781-EB6BAA11-0A3D-4619-9535-D862545C0FE8Q37203904-82B10731-93DA-4BF7-BD5A-8026A1EBEB9EQ38217668-F860ABAE-32F0-4A6A-BA85-3D779F61A03FQ38260025-2D8BFD5D-11A2-404E-A229-23F640C9EA7DQ38609568-133608AE-C410-41F6-9405-64A0B1D07565Q38624965-4BCF89EC-2CCA-4A46-B4E7-48C4DCDED785Q38750453-CACAD028-AB48-4E84-9695-709232BFDADDQ38801873-47261494-4292-46D7-85CC-C4C6CD31A649Q38849874-24F6AA02-A7E6-4A36-B5A3-3E6EBF11F968Q40433535-789B6C4C-8199-40A9-8811-4CCE4E148177Q40867191-794D8E88-C710-4EB5-B067-5A540B976E47Q48072950-7FEC2201-3097-4CB4-9A0B-F08BD7349534Q50138591-F24CA2D3-17F8-49E1-8CD2-F5A7EEB5FDE2Q50190669-0C209A98-00B9-4B7C-A2AD-9E3F0CEBF491Q56910156-34FF6E69-6C45-4E13-9FBF-2908C8CEAAE3
P2860
Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and safety of ...... during the first week of life.
@en
Pharmacokinetics and safety of ...... during the first week of life.
@nl
type
label
Pharmacokinetics and safety of ...... during the first week of life.
@en
Pharmacokinetics and safety of ...... during the first week of life.
@nl
prefLabel
Pharmacokinetics and safety of ...... during the first week of life.
@en
Pharmacokinetics and safety of ...... during the first week of life.
@nl
P2093
P2860
P50
P1476
Pharmacokinetics and safety of ...... during the first week of life.
@en
P2093
Breno Santos
Brian Kearney
Casey Herron
HPTN 057 Protocol Team
Jorge Pinto
Kathleen George
Lynda Emel
Mark Mirochnick
Mary G Fowler
P2860
P356
10.1097/QAI.0B013E3182A921EB
P407
P577
2014-01-01T00:00:00Z